The present disclosure generally relates to systems and methods for detecting viruses, e.g., using microfluidic devices. Certain embodiments are generally directed to systems and methods that are able to detect pathogens such as viruses or bacteria by encapsulating a sample in droplets, and applying amplification reagents to the droplets able to amplify nucleic acids therein, e.g., using loop mediated isothermal amplification (LAMP) or other amplification techniques. In addition, some aspects are generally directed to identifying a species in a sample, e.g., at very low concentrations. In some cases, the sample may be broken into droplets, arid the droplets determined to determine the species.

Systems and methods for determining the presence or absence of an analyte including a nucleic acid (e.g., DNA and RNA), a small molecule (e.g., proteins and amino acid chains), and one or more electrolytes (e.g., Na.sup.+ and K.sup.+). The system or method may detect multiple analytes (e.g., a first DNA and a second DNA) and/or multiple types of analytes (e.g., an RNA and an antibody protein). The signal readout provided by the system or method may be readily understood and may be correlated with a health condition (e.g., hydration or exposure to an infectious agent). The system may be wearable and may analyze one or more biofluids.

Provided herein are methods and compositions for rapid, highly sensitive detection of SARS-CoV-2 in biological samples. In particular, provided herein is a rapid, low-cost method for detecting SARS-CoV-2 that provides reliable, visible test results and does not require PCR reagents, elaborate biosafety precautions, or sophisticated laboratory equipment.

The present invention provides a rapid viral nucleic acid detection kit prepared by using a novel RecA enzyme and the detection method thereof. By editing the recombinase RecA gene, the expressed RecA protein has better solubility and recombinase activity. The RecA protein is used to prepare recombinase dry powder, further the formula of the recombinase dry powder and the ratio are optimized; and specific primers for the ASFV p72 gene are designed for the rapid nucleic acid detection of ASFV, significantly improving the detection sensitivity. In addition, the detection time is short, which effectively avoids missed detection and false detection, and helps prevention of epidemic.

Methods of diagnosing and treating patients afflicted with acne, including diagnosing one as having acne if the individual possesses RT4, RT5, RT7, RT8, RT9, or RT10. Methods for treating acne include administering an effective amount of a drug specifically targeting RT4, RT5, RT7, RT8, RT9, or RT10, such as small molecules, antisense molecules, siRNAs, biologics, antibodies, phages, vaccines, or combination thereof.

Provided is a composition for detecting multiple encephalitis/meningitis/respiratory pathogens. The composition includes primer sequences for the pathogens as shown in SEQ ID NOs: 1-7, 9-23 and 25-32, in which SEQ ID NOs: 1-7 and 9-16 carry fluorescent reporter groups. In addition, the present invention further provides a use of the foregoing composition in the preparation of a kit, and a related kit and a method for using the same.

Disclosed are methods and systems for the detection of variants of the SARS-CoV-2 virus that cause COVID-19. For example, disclosed are methods for identifying and/or tracking variants of SARS-CoV-2 comprising: (a) identifying a sample from a subject as positive for SARS-CoV-2 nucleic acid and/or antibodies to SARS-CoV-2; (b) generating a sample-specific SARS-CoV-2 nucleic acid from the sample; (c) performing nucleic acid sequencing on the sample-specific SARS-CoV-2 nucleic acid; and(d) determining whether the nucleic acid sequence comprises a SARS-CoV-2 variant sequence. Also disclosed are systems for performing any portion of the disclosed methods and computer-program products tangibly embodied in a non-transitory machine-readable storage medium, including instructions configured to perform any of the steps of the disclosed methods or run any portion of the disclosed systems.

A method is for detecting a biomarker within a sample of blood. The method may include processing the sample of blood with a microfluidic blood plasma separator and a plasmonic array biosensor, and flowing the sample of blood over a sensing surface of the plasmonic array biosensor. The sensing surface of the plasmonic array biosensor may have an ssDNA aptamer against the biomarker. The method may further include binding the biomarker in the sample of blood to the ssDNA aptamer of the plasmonic array biosensor, and detecting the biomarker in the sample of blood based upon LSPR altering a reflected optical signal from the plasmonic array biosensor.

Provided herein are methods related to co-packaging of multiple rAAV particles, e.g., by introducing multiple nucleic acid vectors encoding proteins or polypeptides or RNAs of interest into a single cell preparation.

Provided herein are a probe capable of simultaneously detecting a virus and treating virus-infected cells, a composition for detecting a virus, which comprises the probe, a composition for treating a virus, which comprises the probe, and a method of detecting a virus or treating a viral infection by using the same. According to the present disclosure, it is possible to simultaneously perform diagnosis by virus detection and treatment of virus-infected cells, and in particular, diagnosis and treatment may be simultaneously performed on various types of viruses by varying the type of molecular beacon, and thus may be usefully applied to virus diagnosis and treatment fields, which require rapid diagnosis and treatment, and the spread of viral infections may be effectively prevented. In addition, the probe of the present disclosure has excellent stability and excellent detection sensitivity, and thus enables the detection of even a very low amount of a target at the pmole level.